Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Treatment and management of polycythemia vera (PV) requires a coordinated approach that balances disease control with quality‑of‑life considerations. This page is designed for patients traveling to Istanbul for specialized hematology care, as well as for physicians seeking an overview of current therapeutic strategies. Polycythemia vera is a chronic myeloproliferative neoplasm that leads to an overproduction of red blood cells, and if left unchecked, can cause serious complications such as thrombosis, bleeding, and progression to myelofibrosis or acute leukemia.
Worldwide, the incidence of PV is approximately 1–3 cases per 100,000 individuals, and early diagnosis paired with effective treatment and management can dramatically reduce morbidity. Liv Hospital’s JCI‑accredited hematology unit offers a full suite of diagnostic, therapeutic, and supportive services tailored to the needs of international patients, ensuring seamless coordination from the first consultation through long‑term follow‑up.
In the sections below, we explore the disease’s pathophysiology, outline the core therapeutic options, describe monitoring protocols, discuss symptom control, and highlight how Liv Hospital personalizes care for patients arriving from abroad. Whether you are newly diagnosed or looking to optimize an existing care plan, the information provided will help you understand the comprehensive strategy behind successful treatment and management of polycythemia vera.
Polycythemia vera is characterized by a mutation in the JAK2 V617F gene in more than 95 % of cases, leading to autonomous proliferation of erythroid, myeloid, and megakaryocytic lineages. The disease typically presents with elevated hemoglobin/hematocrit, splenomegaly, and a range of constitutional symptoms such as pruritus, fatigue, and headaches.
Key clinical milestones include:
Understanding these elements is essential for clinicians to tailor treatment and management plans that address both immediate hematologic control and long‑term disease monitoring. At Liv Hospital, a multidisciplinary team—including hematologists, radiologists, and supportive‑care specialists—reviews each case to determine the most appropriate therapeutic pathway.
The cornerstone of PV treatment and management is maintaining hematocrit below 45 % to reduce thrombotic risk. This is achieved through a combination of phlebotomy, low‑dose aspirin, and cytoreductive agents when indicated.
Therapeutic modalities include:
Selection of therapy depends on risk stratification, comorbidities, and patient preferences. The table below outlines the typical indications, dosing considerations, and common side effects for each option.
Liv Hospital’s hematology team conducts comprehensive baseline assessments—including complete blood count, iron studies, and cardiovascular evaluation—before initiating any cytoreductive therapy, ensuring that each patient receives a safe and effective regimen.
Effective treatment and management extends beyond initial therapy; it requires ongoing surveillance to detect disease progression, treatment toxicity, and emerging complications.
Key monitoring components are:
Liv Hospital provides an integrated electronic health record system that allows patients to upload home‑monitoring data (e.g., blood pressure, weight) securely. This facilitates remote review by the treating hematologist, reducing the need for frequent in‑person visits while maintaining high‑quality oversight.
Beyond controlling blood counts, treatment and management must address the myriad symptoms that affect daily living. Common issues include pruritus after hot showers, erythromelalgia, and microvascular disturbances.
Symptom‑focused interventions include:
Patients receive personalized education on lifestyle modifications, such as staying well‑hydrated, avoiding smoking, and wearing compression stockings when indicated. Liv Hospital’s supportive‑care nurses conduct regular symptom assessments and adjust supportive medications promptly.
International patients face unique logistical challenges that can impact the continuity of treatment and management. Liv Hospital’s dedicated International Patient Services team streamlines every step of the journey, from visa assistance to post‑procedure follow‑up.
Key services include:
By integrating clinical excellence with logistical support, Liv Hospital enables patients to focus on their health rather than administrative hurdles, thereby enhancing adherence to long‑term treatment and management protocols.
Research into polycythemia vera continues to evolve, offering hope for more targeted and less toxic options. Current investigational approaches under clinical evaluation include next‑generation JAK inhibitors, interferon‑beta formulations, and agents targeting the inflammatory microenvironment.
Selected ongoing trials relevant to PV patients:
Liv Hospital actively participates in multinational research networks, allowing eligible patients to enroll in these trials with minimal disruption to their standard care. Physicians can discuss trial availability during the initial consultation, ensuring that patients have access to cutting‑edge therapies when appropriate.
Liv Hospital combines JCI‑accredited clinical expertise with a patient‑centric environment designed for international visitors. Our hematology department boasts board‑certified specialists experienced in managing polycythemia vera and related myeloproliferative disorders. State‑of‑the‑art facilities, including a dedicated infusion suite and advanced imaging, enable precise diagnosis and safe delivery of complex therapies such as interferon‑α and ruxolitinib.
Beyond medical excellence, we provide comprehensive support services—from visa assistance to multilingual care coordination—ensuring a seamless experience from arrival to discharge. Choosing Liv Hospital means receiving world‑class treatment backed by a compassionate, globally aware team.
Ready to take control of your health journey? Contact Liv Hospital today to schedule a personalized consultation with our hematology experts. Our international patient team will guide you through every step, from travel arrangements to post‑treatment follow‑up.
Liv Hospital Vadistanbul
Prof. MD. Itır Şirinoğlu Demiriz
Hematology
Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan
Pediatric Hematology and Oncology
Liv Hospital Ankara
Assoc. Prof. MD. Ramazan Öcal
Hematology
Liv Hospital Ankara
Prof. MD. Meral Beksaç
Hematology
Liv Hospital Ankara
Prof. MD. Oral Nevruz
Hematology
Liv Hospital Gaziantep
Assoc. Prof. MD. Fadime Ersoy Dursun
Hematology
Spec. MD. Ceyda Aslan
Hematology
Spec. MD. Elmir İsrafilov
Hematology
Spec. MD. Minure Abışova Eliyeva
Hematology
Liv Hospital Ulus + Liv Hospital Bahçeşehir
Prof. MD. Mehmet Hilmi Doğu
Hematology
Send us all your questions or requests, and our expert team will assist you.
Polycythemia vera treatment focuses on reducing blood viscosity by maintaining hematocrit at or below 45 %. This is achieved through regular phlebotomy, low‑dose aspirin, and, when needed, cytoreductive drugs such as hydroxyurea or interferon‑α. Keeping the hematocrit in this range has been shown in multiple studies to significantly decrease the incidence of arterial and venous thromboses, which are the leading cause of morbidity in PV patients. The strategy also includes monitoring for disease progression and managing symptoms that affect quality of life.
Hydroxyurea is indicated for PV patients classified as high‑risk, which includes individuals older than 60 years or those who have experienced a thrombotic event. It works by suppressing bone‑marrow proliferation, thereby lowering red‑cell mass and platelet counts. Dosing typically starts at 15–20 mg/kg/day and is titrated to achieve target blood counts while monitoring for side effects such as myelosuppression and mucocutaneous ulcers. In younger patients or those planning pregnancy, alternative agents like interferon‑α are preferred.
Ruxolitinib targets the JAK‑STAT pathway directly, offering a mechanism distinct from cytoreductive agents that mainly suppress cell proliferation. It is approved for PV patients who have failed or cannot tolerate hydroxyurea. Typical dosing starts at 10 mg twice daily, with adjustments based on blood counts and tolerability. Benefits include reduction of splenomegaly and symptom burden, but clinicians must monitor for infections, anemia, and weight gain. Clinical trials have demonstrated its efficacy in maintaining hematocrit control and improving quality‑of‑life scores.
After initiating any cytoreductive drug, patients should have a complete blood count with differential every 1–3 months to ensure hematocrit stays ≤ 45 % and to detect cytopenias early. Periodic JAK2 V617F allele burden testing helps assess molecular response, especially for targeted agents like ruxolitinib. Annual cardiovascular assessments—including blood pressure, lipid profile, and ECG—are recommended because PV patients have heightened cardiovascular risk. Imaging, typically abdominal ultrasound or MRI, monitors spleen size annually or when symptoms suggest enlargement.
Pruritus after hot showers is common in PV and is usually treated with antihistamines; if ineffective, selective serotonin reuptake inhibitors (SSRIs) or phototherapy (PUVA) may be added. Erythromelalgia, a painful burning sensation in the extremities, responds well to low‑dose aspirin (81 mg) combined with calcium channel blockers such as nifedipine. Gabapentin or other neuropathic agents can be considered as adjuncts. Addressing these symptoms improves daily functioning and overall quality of life.
International patients receive a dedicated service team that handles visa support, airport transfers, and vetted hotel arrangements near the hospital. Professional interpreters fluent in English, Arabic, Russian, and several European languages ensure clear communication during consultations. All medical records are securely translated and electronically shared with the patient’s home physician. After discharge, tele‑medicine appointments allow continuous monitoring, while personalized care plans are adjusted for travel dates, time‑zone differences, and medication availability, facilitating adherence to long‑term treatment protocols.
BlogHematologyApr 08, 2026Did you know that blood disorders affect millions of people worldwide, causing a wide range of health issue...
BlogHematologyApr 07, 2026Every year, over 1.8 million people in the United States get cancer. Hematology oncology is key in fighting...
BlogHematologyApr 06, 2026Pulmonary hemorrhage is a serious condition where blood enters the lung tissue and airways suddenly or over...
BlogHematologyApr 03, 2026Vitamin B12 and folic acid are key nutrients. They help keep red blood cells healthy, support nerve functio...
BlogHematologyApr 03, 2026Vitamin B is key for our health, helping with energy and brain function. At LivHospital, we know how import...
BlogHematologyApr 03, 2026Vitamin B12 and folate (vitamin B9) are essential nutrients for our nerves and for making red blood cells. ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 26 75